F
Fabian Gross
Researcher at University of Toulouse
Publications - 14
Citations - 6604
Fabian Gross is an academic researcher from University of Toulouse. The author has contributed to research in topics: Genetic enhancement & Pancreatic cancer. The author has an hindex of 7, co-authored 11 publications receiving 6316 citations. Previous affiliations of Fabian Gross include University of Paris.
Papers
More filters
Journal ArticleDOI
LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1.
Salima Hacein-Bey-Abina,C von Kalle,C von Kalle,Manfred Schmidt,Matthew P. McCormack,NM Wulffraat,Philippe Leboulch,Annick Lim,Cameron S. Osborne,R. Pawliuk,Estelle Morillon,R. Sorensen,A. Forster,Peter Fraser,Jeffrey I. Cohen,G de Saint Basile,Ian E. Alexander,Uwe Wintergerst,Thierry Frebourg,Alain Aurias,Dominique Stoppa-Lyonnet,Serge Romana,I. Radford-Weiss,Fabian Gross,Françoise Valensi,Eric Delabesse,Elizabeth Macintyre,F. Sigaux,Jean Soulier,L. E. Leiva,Manuela Wissler,Claudia Prinz,Terence H. Rabbitts,F. Le Deist,Alain Fischer,Marina Cavazzana-Calvo +35 more
TL;DR: Retrovirus vector insertion can trigger deregulated premalignant cell proliferation with unexpected frequency, most likely driven by retrovirus enhancer activity on the LMO2 gene promoter.
Journal ArticleDOI
Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease
Marina Cavazzana-Calvo,Hacein-Bey S,Geneviève de Saint Basile,Fabian Gross,Eric Yvon,Patrick Nusbaum,Françoise Selz,Christophe Hue,Stéphanie Certain,Jean-Laurent Casanova,Philippe Bousso,Françoise Le Deist,Alain Fischer +12 more
TL;DR: A gene therapy trial for SCID-X1 was initiated, based on the use of complementary DNA containing a defective gammac Moloney retrovirus-derived vector and ex vivo infection of CD34+ cells, which provided full correction of disease phenotype and clinical benefit.
Journal ArticleDOI
Phase I trial: the use of autologous cultured adipose-derived stroma/stem cells to treat patients with non-revascularizable critical limb ischemia
Alessandra Bura,Valérie Planat-Benard,Philippe Bourin,Jean-Sébastien Silvestre,Fabian Gross,Jean-Louis Grolleau,Bertrand Saint-Lebese,Julie-Anne Peyrafitte,Sandrine Fleury,Mélanie Gadelorge,Marion Taurand,Sophie Dupuis-Coronas,Bertrand Leobon,Louis Casteilla +13 more
TL;DR: The feasibility and safety of autologous ASC transplantation in patients with objectively proven CLI not suitable for revascularization are demonstrated and the improved wound healing also supports a putative functional efficiency.
Journal ArticleDOI
Intramyocardial transplantation of mesenchymal stromal cells for chronic myocardial ischemia and impaired left ventricular function: Results of the MESAMI 1 pilot trial
Damien Guijarro,M. Lebrin,Olivier Lairez,Olivier Lairez,Philippe Bourin,Nicolas Piriou,Joffrey Pozzo,Joffrey Pozzo,Gilles Lande,Matthieu Berry,T. Le Tourneau,Daniel Cussac,Luc Sensebé,Fabian Gross,Guillaume Lamirault,A. Huynh,Alain Manrique,J.B. Ruidavet,Meyer Elbaz,Jean-Noël Trochu,Angelo Parini,S. Kramer,Michel Galinier,Patricia Lemarchand,Jerome Roncalli,Jerome Roncalli +25 more
TL;DR: The results suggest that autologous MSCs can be safely administered to the hearts of patients with severe, chronic, reversible myocardial ischemia and impaired cardiac function and may be associated with improvements in cardiac performance, LV remodeling, and patient functional status.
Journal ArticleDOI
Optimization of retroviral gene transfer protocol to maintain the lymphoid potential of progenitor cells.
Salima Hacein-Bey,Fabian Gross,Patrick Nusbaum,Christophe Hue,Yamina Hamel,Alain Fischer,Marina Cavazzana-Calvo +6 more
TL;DR: These conditions were adopted for a clinical trial of gene therapy for X-linked severe combined immunodeficiency, and the combination of SCF + FL + M-GDF + IL-3 maintained more efficiently the lymphoid potential of the progeny of transduced long term-cultured CD34(+) cells.